Saturday, December 3, 2011
COAGULATION CORNER: DECEMBER 2011
COAGULATION 2011: YEAR IN REVIEW
It is hard to believe another year has gone by, as I get older time passes much more quickly. The end of a year is time that we reflect what has happened, review what has been positive or negative and try to rejuvenate to begin the next year.
So what has 2011 brought us in the coagulation world? Where have the advances been, what have been the biggest issues, and what is the future? I think the hottest topic is anticoagulation. For so many years there have been limited options, and now the field has exploded. Have heparin, and warfarin out lived there time? Will they become the 8 track players of coagulation? (for those of you who don’t know what an 8 track player is- google it) I am not about to take that stand. Not until we have more information on the new anticoagulants and how to reverse them, and more importantly how to monitor them. If we have learned nothing else this year, it is that the oral direct thrombin inhibitors and oral Xa inhibitors are not a perfect science. They can place patients at a risk for bleeding, additionally, how is one to know if patients are complying with dosing? It is an oral anticoagulant- compliance is a big issue- and there is no way to check what a patient has on board.
What has happened to thrombin generation? Just two years ago, every other abstract looked at thrombin generation. Okay, so the assay is not ready for prime time, so is this the tape cassette of coagulation, was good for awhile, but we know that something better is out there? Do you know that an APTT only measures 2% of thrombin generated? Thrombotic events are on the rise, we need to not only be able to diagnose patients, but understand who is at risk and focus on prevention.
Ah, platelets, let us not forget out little friends- and maybe learn that they do have a nucleus of sort- and that they roll along, as they gather together! Another huge issue, does aspirin really help? Should dual anti-platelet therapy be used? What about genetic mutations? Increasing doses to overcome them works, but can put a patient at a risk for bleeding- wouldn’t it be easier to test patients for the mutations? Cost, yes it costs, but again, we have the knowledge available, shouldn’t we put it to good use and improve patient outcomes?
Next issue, pregnancy and thrombosis, big issue- why do we not screen women? Why in this day in age, when we have the technology do we still wait for women to have 3 miscarriages before we look for a cause for thrombosis? Again the cost, how much is the cost of treating patients after a miscarriage versus a thrombotic workup? We have so many synergistic issues that put women at risk- pregnancy itself is a thrombotic state, add thyroid disease, homocysteine, folic acid levels, and I haven’t even mentioned genetic mutations- MTHFR, Prothrombin mutation, FV Leiden, PAI-1, as well as sedentary life styles and obesity. Again, technology is there, shouldn’t we use it? On the flip side, excess bleeding during menstruation- your grandmother, your mother, your daughter. This is a pattern, it is not acceptable to say we are all bleeders- when it impacts your quality of life- don’t be a martyr- ask questions- ask to be tested, you might have Von Willebrands disease.
So, that is my soap box issues for the year 2011. I can’t close out the year without some type of holiday cheer- so here is my version of:
Walking in a Winter Wonderland- or
Factors activate are you ready
Gone away is the bleeding
But wait that clot is getting much larger
Later on, we’ll switch to warfarin
In the case we need to use another
When it works, ain’t it thrilling
Have a wonderful Holiday season, all the best and happiness in 2012-
About the Author
NEW BLOGSCoagulation Corner
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.